

Señores

DIVISION DE NUEVAS CREACIONES

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Bogotá, D.C.

Re.: Expediente No. 01 - 19.686

Solicitud de Patente

SUPERINTENDENCIA Y COMERCIO
Radicacion : 01019686 00000001 Folios: 50
Fecha (RM): 2001-03-30 12:58:44
Tramite : 002 PATENTE: 0 1 REGISTRO/ 329 COMPLEMEN
Dependencia: 2000 DIVISION DE NUEVAS CREACIONES

Debidamente traducida, adjunto acompaño la copia oficial de la solicitud de patente básica estadounidense No. 60/188.410 la cual le solicito agregar a este expediente para los efectos legales respectivos.

De Ustedes atentamente,

GERMAN CASTILLO GRAU

T.P. No. 2978 del C.S.J.



A TODOS A QUIENES LLEGUE EL PRESENTE:

DEPARTAMENTO DE COMERCIO DE LOS ESTADOS UNIDOS

Oficina de Marcas y Patentes

31 de enero de 2001

LA PRESENTE CERTIFICA QUE LA ADJUNTA ES UNA COPIA TOMADA DE LOS REGISTROS DE LA OFICINA DE MARCAS Y PATENTES DE LOS ESTADOS UNIDOS, DE LOS DOCUMENTOS DE LA SOLICITUD DE PATENTE ABAJO IDENTIFICADA Y LA CUAL CUMPLE CON LOS REQUISITOS PARA QUE LE SEA CONFERIDA UNA FECHA DE RADICACIÓN SEGÚN 35 USC 111.

NÚMERO DE SOLICITUD 60/188.410

FECHA DE RADICACIÓN: 2 de marzo de 2000

Por Autoridad del

COMISIONADO DE MARCAS Y PATENTES

(FIRMA) N. WILLIAMS

Oficial de Certificaciones

(SELLO DORADO DE OBLEA)


*** * * ***

65 ~~9A~~


ANTAGONISTAS DEL RECEPTOR IL-8

REIVINDICACIONES:

1. Un compuesto de la fórmula (I):



en donde
Y



en donde

R_b es independientemente seleccionado del grupo compuesto por hidrógeno, NR_6R_7 , OH, OR_a , alquilo C_{1-5} , arilo, arilo-alquilo C_{1-4} , arilo, alqueno C_{2-4} ; cicloalquilo, cicloalquilo alquilo C_{1-5} , heteroarilo, heteroarilo-alquilo C_{1-4} , heteroarilo-alqueno C_{2-4} , heterocíclico, heterocíclico-alquilo C_{1-4} o un medio heterocíclico-alqueno C_{2-4} , todos cuyos medios pueden ser sustituido opcionalmente una o tres veces independientemente por un sustituyente seleccionado del grupo compuesto por halógeno; alquilo C_{1-4} sustituido por halo; alquilo C_{1-4} ; amino, amina sustituida por mono o di-alquilo C_{1-4} ; OR_a ; $C(O)R_a$; $NR_6C(O)OR_a$; $OC(O)NR_6R_7$; hidroxí; $NR_6C(O)R_a$; $S(O)_mR_a$; $C(O)NR_6R_7$; $C(O)OH$; $C(O)OR_a$; $S(O)NR_6R_7$; $NHS(O)_2R_a$; o los dos sustituyentes R_b pueden unirse para formar un anillo de 3 a 10 miembros, sustituido opcionalmente y que contengan además de carbono,

66 AC

independientemente, de 1 a 3 medios sustituidos opcionalmente seleccionados del grupo compuesto por NR_6 , O, S, SO, o SO_2 medios que opcionalmente pueden ser insaturados;

R_6 es seleccionado del grupo compuesto por alquilo, arilo arilo-alquilo C_{1-4} , heteroarilo, heteroarilo-alquilo C_{1-4} , heterocíclico, COOR_{13} , o un medio heterocíclico-alquilo C_{1-4} , todos los cuales pueden ser sustituido opcionalmente;

m es un entero con un valor de 1 a 3;

m' es 0 o un entero con un valor de 1 o 2;

n es un entero con valor de 1 a 3;

q es 0, o un entero con un valor de 1 a 10;

t es 0 o un entero con un valor de 1 o 2;

s es un entero con un valor de 1 a 3;

R_1 es seleccionado independientemente del grupo compuesto por hidrógeno, halógeno, nitro, ciano, alquilo C_{1-10} , alquilo C_{1-10} sustituido por halo, alqueno C_{2-10} , alcoxi C_{1-10} alcoxi C_{1-10} sustituido por halo, azida, $\text{S(O)}_t\text{R}_4$, $(\text{CR}_8\text{R}_9)_q\text{S(O)}_t\text{R}_4$, hidroxilo, alquilo C_{1-4} sustituido por hidroxilo, arilo, arilo-alquilo C_{1-4} , arilo-alqueno C_{2-10} , ariloxi, arilo-alquilo C_{1-4} , heteroarilo, heteroarilalquilo, heteroarilo-alqueno C_{2-10} , heteroarilo-alquilo C_{1-4} , heterocíclico, heterocíclico-alquilo C_{1-4} , heterocíclico-alquilo C_{1-4} , heterocíclico-alqueno C_{2-10} , $(\text{CR}_8\text{R}_9)_q\text{NR}_4\text{R}_5$, $(\text{CR}_8\text{R}_9)_q\text{C(O)}\text{NR}_4\text{R}_5$, alqueno C_{2-10} $\text{C(O)}\text{NR}_4\text{R}_5$, $(\text{CR}_8\text{R}_9)_q\text{C(O)}\text{NR}_4\text{R}_{10}$, $\text{S(O)}_3\text{R}_6$, $(\text{CR}_8\text{R}_9)_q\text{C(O)}\text{R}_{11}$, alqueno C_{2-10} $\text{C(O)}\text{R}_{11}$, alqueno C_{2-10} $\text{C(O)}\text{OR}_{11}$, $(\text{CR}_8\text{R}_9)_q\text{C(O)}\text{OR}_{11}$, $(\text{CR}_8\text{R}_9)_q\text{OC(O)}\text{R}_{11}$, $(\text{CR}_8\text{R}_9)_q\text{NR}_4\text{C(O)}\text{R}_{11}$, $(\text{CR}_8\text{R}_9)_q\text{C(NR}_4)\text{NR}_4\text{R}_5$, $(\text{CR}_8\text{R}_9)_q\text{NR}_4\text{C(NR}_5)\text{R}_{11}$, $(\text{CR}_8\text{R}_9)_q\text{NHS(O)}_2\text{R}_{13}$, $(\text{CR}_8\text{R}_9)_q\text{S(O)}\text{SNR}_4\text{R}_5$, o dos medios R_1 juntos pueden formar $\text{O}-(\text{CH}_2)_n\text{O}$ o un anillo saturado o insaturado de 5 a 6 miembros, de modo que los medios de alquilo, arilo, arilalquilo, heteroarilo o heterocíclico puedan ser sustituidos opcionalmente;

67 27

R_4 y R_5 son seleccionados independientemente del grupo compuesto por hidrógeno, alquilo C_{1-4} sustituido opcionalmente, arilo sustituido opcionalmente, arilo-alquilo C_{1-4} sustituido opcionalmente, heteroarilo sustituido opcionalmente, heteroarilo-alquilo C_{1-4} sustituido opcionalmente, heterocíclico, heterocíclico-alquilo C_{1-4} , o R_4 y R_5 junto con el nitrógeno al que están fijos forman un anillo de 5 a 7 miembros que opcionalmente pueden comprender un heteroátomo adicional seleccionado de O, N y S;

R_6 y R_7 son seleccionados independientemente del grupo compuesto por hidrógeno, o un alquilo C_{1-4} , heteroarilo, arilo, alquilarilo, alquilo-heteroalquilo C_{1-4} o R_6 y R_7 junto con el nitrógeno al que están fijos forman un anillo de 5 a 7 miembros que opcionalmente puede contener un heteroátomo adicional seleccionado de oxígeno, nitrógeno o azufre, y cuyo anillo puede ser sustituido opcionalmente;

Y es seleccionado del grupo compuesto por furano, tiofeno, pirrol, oxazol, imidazol, tiazol, pirazol, isooxazol, isotiazol, 1,2,3 o 1,2,4 oxadiazol, 1,2,3 o 1,2,4 triazol, 1,2,3 o 1,2,4 tiadiazol, piridina, irimidina, piridazina, pirazina, 1,3,5 o 1,2,3 o 1,2,4 triazina, 1,2,4,5 tetrazina, indol, benzofuran, indazol, benzimidazol, benzotiazol, quinolina, isoquinolina, cinolina, ftalazina, quinazolina, quinoxalina, todos cuyos medios pueden ser sustituidos de 1 a 3 veces por R_1 .

R_8 es hidrógeno o alquilo C_{1-4} ;

R_9 es alquilo C_{1-4} ;

R_{10} es alquilo C_{1-10} $C(O)_2R_8$;

R_{11} es seleccionado del grupo compuesto por hidrógeno, alquilo C_{1-4} sustituido opcionalmente, arilo sustituido opcionalmente, ariloalquilo C_{1-4} sustituido opcionalmente, heteroarilo sustituido opcionalmente, heteroarilo-alquilo C_{1-4} sustituido opcionalmente, heterocíclico sustituido opcionalmente, o heterocíclico-alquilo C_{1-4} sustituido opcionalmente; y

68
9X

R_{13} es seleccionado del grupo compuesto por alquilo C_{1-4} , arilo, arilo-alquilo C_{1-4} , heteroarilo, heteroarilo-alquilo C_{1-4} , heterocíclico y heterocíclico-alquilo C_{1-4} ;

o una sal farmacéuticamente aceptable de lo mismo.

2. El compuesto según la Reivindicación 1, en donde R_1 es sustituido en la posición 4 por un electrón que retira el medio.

3. El compuesto según la Reivindicación 3, en donde R_1 es halógeno, ciano o nitro.

4. El compuesto según la Reivindicación 3, en donde R_1 es halógeno.

5. El compuesto según la Reivindicación 4, en donde R_1 es independientemente, flúor, cloro o bromo.

6. El compuesto según la Reivindicación 1, en donde Y es mono sustituida en la posición 2' o en la posición 3', o disustituida en la posición 2' o 3' de un anillo monocíclico.

7. El compuesto según la Reivindicación 6 en donde Y es piridina y pirazol.

8. El compuesto según la Reivindicación 1, en donde R_b es hidrógeno, alquilo C_{1-4} , o alquilo C_{1-4} sustituido por $C(O)OH$ o $C(O)OR_a$.

9. El compuesto según la Reivindicación 1, que es:

N-(3-aminosulfonilo-4-cloro-3-hidroxifenilo)-N'-(piridin-2-ilo)urea;

N-(3-aminosulfonilo-4-cloro-3-hidroxifenilo)-N'-(2-cloro-piridin-3-il)urea;

N-(3-aminosulfonilo-4-cloro-3-hidroxifenilo)-N'-(1-fenilo-1H-1,2,3-triazol-5-ilo)urea;

N-(3-aminosulfonilo-4-cloro-3-hidroxifenilo)-N'-(1,3-dimetilpirazol-5-ilo)urea;

6

69 

N-(3-aminosulfonilo-4-cloro-3-hidroxifenilo)-N'-(1-metilpirazol-5-ilo)urea; y

N-(3-aminosulfonilo-4-cloro-3-hidroxifenilo)-N'-(2-metil-piridin-3-ilo)urea.

10. Un compuesto según la reivindicación 9, en donde el compuesto es en su forma de sal sódica.

11. Un compuesto según la Reivindicación 10, en donde el compuesto es en su forma de sal potásica.

12. Una composición farmacéutica que comprende un compuesto según cualquiera de las Reivindicaciones 1 a 11, y un vehículo o diluyente farmacéuticamente aceptable.

13. Un método para tratar una enfermedad mediada por quimiocina, en donde la quimiocina se liga a un receptor IL-8 a o b, cuyo método consiste en administrar a dicho mamífero una cantidad efectiva de un compuesto de la fórmula según cualquiera de las Reivindicaciones 1 a 11.


14. El método según la Reivindicación 13, en donde el mamífero sufre de una enfermedad mediada por quimiocina seleccionada del grupo compuesto por: psoriasis, dermatitis atópica, osteoartritis, artritis reumatoide, asma, enfermedad pulmonar obstructiva crónica, síndrome de agotamiento respiratorio en adultos, enfermedad de intestinos inflamados, enfermedad de Crohn, colitis ulcerativa, ataque, shock séptico, esclerosis múltiple, shock entodóxico, sepsis gram negativa, síndrome de shock tóxico, lesión de reperfusión renal y cardíaca, glomerulonefritis, trombosis, reacción injerto-anfitrión, enfermedad de Alzheimer, rechazos a injertos, malaria, restenosis, angiogenesis, aterosclerosis, osteoporosis, gingivitis y liberación no deseada de células hematopoiéticas y enfermedades causadas por virus respiratorios, virus de herpes y virus de hepatitis, meningitis, fibrosis cística, trabajo de parto antes de tiempo, tos, prurito, disfunción de órganos múltiples, trauma, tensiones, desgarres, contusiones, artritis psoriática, herpes, encefalitis, vasculitis SNC, lesión cerebral traumática, tumores del SNC, hemorragia subaracnoide, trauma posquirúrgico, neumonitis

Y

30 26

intersticial, hipersensibilidad, artritis inducida por cristales, pancreatitis crónica, hepatitis alcohólica, enterocolitis necrotizante, sinusitis crónica, uveitis, polimiositis, vasculitis, acné, úlceras gástricas y duodenales, enfermedad celíaca, esofagitis, glositis, obstrucción de las vías respiratorias, hiperrespuesta de las vías respiratorias, bronquiolitis, obliterantes de bronquiolitis, neumonía, bronquiectasis, bronquiolitis, obliterantes de bronquilitis, bronquitis crónica, cor pulmonale, disnea, enfisema, hipercapnea, hiperinflación, hipoxemia, inflamaciones inducidas por hiperoxia, hipoxia, reducción en el volumen pulmonar por cirugía, fibrosis pulmonar, hipertensión pulmonar, hipertrofia ventricular derecha, sarcoidosis, enfermedad de las vías respiratorias pequeñas, no concordancia ventilación-perfusión, resuello, gripes y lupus.

71 ~~72~~



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

January 31, 2001

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/188,410

FILING DATE: March 10, 2000



**By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS**

N. WILLIAMS

Certifying Officer

A/PROV
72 ~~40~~

Express Mail® Mailing Label Number EL175493275US

4 Date Of Deposit: 10 March 2002

I Herby Certify That This Paper Or Fee Is Being Deposited With The United States Postal Service "Express Mail Post Office To Addressee" Service Under 37 CFR 1.10 On The Date Indicated Above And Is Addressed To: Assistant Commissioner for Patents, Washington, D.C. 20231.

Name Of Person Mailing Paper Or Fee

(Type Or Print) SUSAN H. GALON

Signature: James M. Salter

1:541 U.S. Pto
60/108410
Ms. 10/00

This is a request for filing a PROVISIONAL APPLICATION for PATENT under 37 CFR 1.53(c).

60188410.031000

ENCLOSED APPLICATION PARTS (check all that apply)			
☒ Specification	Number of Pages	40	☐ Small Entity Statement
☐ Drawings	Number of Sheets		☐ Other (specify)

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT		
☒ The Commissioner is hereby authorized to charge filing fees and credit Deposit Account No. 19-2570	PROVISIONAL FILING FEE AMOUNT (\$)	<u>\$150.00</u>

Respectfully submitted,
Signature:

Soma G. Simon

Date:

Registration No.: **37,444**

☐ Additional inventors are being named on separately numbered sheets attached hereto.

PROVISIONAL APPLICATION FILING ONLY

SEND TO: Assistant Commissioner for Patents, Box Provisional Application, Washington, D.C. 20231.

N:\SOMAYCASES\PS1108\PTP\rev.doc

73 79

IL-8 RECEPTOR ANTAGONISTS**FIELD OF THE INVENTION**

This invention relates to novel sulfonamide substituted diphenyl urea compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating IL-8, GRO α , GRO β , GRO γ , NAP-2, and ENA-78 mediated diseases.

BACKGROUND OF THE INVENTION

Many different names have been applied to Interleukin-8 (IL-8), such as neutrophil attractant/activation protein-1 (NAP-1), monocyte derived neutrophil chemotactic factor (MDNCF), neutrophil activating factor (NAF), and T-cell lymphocyte chemotactic factor. Interleukin-8 is a chemoattractant for neutrophils, basophils, and a subset of T-cells. It is produced by a majority of nucleated cells including macrophages, fibroblasts, endothelial and epithelial cells exposed to TNF, IL-1 α , IL-1 β or LPS, and by neutrophils themselves when exposed to LPS or chemotactic factors such as FMLP. M. Baggiolini et al., *J. Clin. Invest.* 84, 1045 (1989); J. Schroder et al., *J. Immunol.* 139, 3474 (1987) and *J. Immunol.* 144, 2223 (1990); Strieter, et al., *Science* 243, 1467 (1989) and *J. Biol. Chem.* 264, 10621 (1989); Cassatella et al., *J. Immunol.* 148, 3216 (1992).

GRO α , GRO β , GRO γ and NAP-2 also belong to the chemokine family. Like IL-8 these chemokines have also been referred to by different names. For instance GRO α , β , γ have been referred to as MGS α , β and γ respectively (Melanoma Growth Stimulating Activity), see Richmond et al., *J. Cell Physiology* 129, 375 (1986) and Chang et al., *J. Immunol.* 148, 451 (1992). All of the chemokines of the α -family which possess the ELR motif directly preceding the CXC motif bind to the IL-8 B receptor (CXCR2).

IL-8, GRO α , GRO β , GRO γ , NAP-2, and ENA-78 stimulate a number of functions in vitro. They have all been shown to have chemoattractant properties for neutrophils, while IL-8 and GRO α have demonstrated T-lymphocytes, and basophilic chemotactic activity. In addition IL-8 can induce histamine release from basophils from both normal and atopic individuals. GRO- α and IL-8 can in addition, induce lysosomal enzyme release and respiratory burst from neutrophils. IL-8 has also been shown to increase the surface expression of Mac-1 (CD11b/CD18) on

SQ188410-031000

11

74 80

neutrophils without de novo protein synthesis.. This may contribute to increased adhesion of the neutrophils to vascular endothelial cells. Many known diseases are characterized by massive neutrophil infiltration. As IL-8, GRO α , GRO β , GRO γ and NAP-2 promote the accumulation and activation of neutrophils, these chemokines

5 have been implicated in a wide range of acute and chronic inflammatory disorders including psoriasis and rheumatoid arthritis, Baggiolini et al., FEBS Lett. 307, 97 (1992); Miller et al., Crit. Rev. Immunol. 12, 17 (1992); Oppenheim et al., Annu. Rev. Immunol. 9, 617 (1991); Seitz et al., J. Clin. Invest. 87, 463 (1991); Miller et al., Am. Rev. Respir. Dis. 146, 427 (1992); Donnelly et al., Lancet 341, 643 (1993).

10 In addition the ELR chemokines (those containing the amino acids ELR motif just prior to the CXC motif) have also been implicated in angiostasis, Strieter et al., Science 258, 1798 (1992).

In vitro, IL-8, GRO α , GRO β , GRO γ and NAP-2 induce neutrophil shape change, chemotaxis, granule release, and respiratory burst, by binding to and

15 activating receptors of the seven-transmembrane, G-protein-linked family, in particular by binding to IL-8 receptors, most notably the IL-8 β receptor (CXCR2). Thomas et al., J. Biol. Chem. 266, 14839 (1991); and Holmes et al., Science 253, 1278 (1991). The development of non-peptide small molecule antagonists for members of this receptor family has precedent. For a review see R. Freidinger in:

20 Progress in Drug Research, Vol. 40, pp. 33-98, Birkhauser Verlag, Basel 1993. Hence, the IL-8 receptor represents a promising target for the development of novel anti-inflammatory agents.

Two high affinity human IL-8 receptors (77% homology) have been characterized: IL-8R α , which binds only IL-8 with high affinity, and IL-8R β , which

25 has high affinity for IL-8 as well as for GRO α , GRO β , GRO γ and NAP-2. See Holmes et al., supra; Murphy et al., Science 253, 1280 (1991); Lee et al., J. Biol. Chem. 267, 16283 (1992); LaRosa et al., J. Biol. Chem. 267, 25402 (1992); and Gayle et al., J. Biol. Chem. 268, 7283 (1993).

There remains a need for treatment, in this field, for compounds, which are

30 capable of binding to the IL-8 α or β receptor. Therefore, conditions associated with an increase in IL-8 production (which is responsible for chemotaxis of neutrophil

75 ~~84~~

and T-cells subsets into the inflammatory site) would benefit by compounds, which are inhibitors of IL-8 receptor binding.


SUMMARY OF THE INVENTION

This invention provides for a method of treating a chemokine mediated
5 disease, wherein the chemokine is one which binds to an IL-8 a or b receptor and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In particular the chemokine is IL-8.

This invention also relates to a method of inhibiting the binding of IL-8 to its
10 receptors in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).

The present invention also provides for the novel compounds of Formula (I), and pharmaceutical compositions comprising a compound of Formula (I), and a pharmaceutical carrier or diluent.

15 Compounds of Formula (I) useful in the present invention are represented by the structure:



20 wherein

R_b is independently selected from the group consisting of hydrogen, NR_6R_7 , OH, OR_a , C_{1-5} alkyl, aryl, aryl C_{1-4} alkyl, aryl C_{2-4} alkenyl, cycloalkyl, cycloalkyl C_{1-5} alkyl, heteroaryl, heteroaryl C_{1-4} alkyl, heteroaryl C_{2-4} alkenyl, heterocyclic, heterocyclic C_{1-4} alkyl, and a heterocyclic C_{2-4} alkenyl moiety, all of which moieties may be
25 optionally substituted one to three times independently by a substituent selected from the group consisting of halogen, nitro, halosubstituted C_{1-4} alkyl, C_{1-4} alkyl, amino, mono or di- C_{1-4} alkyl substituted amine, OR_a , $C(O)R_a$, $NR_aC(O)OR_a$, $OC(O)NR_6R_7$, hydroxy, $NR_9C(O)R_a$, $S(O)_mR_a$, $C(O)NR_6R_7$, $C(O)OH$, $C(O)OR_a$,

76 gr

S(O)₂NR₆R₇ and NHS(O)₂R₈; or the two R₆ substituents join to form a 3-10 membered ring, optionally substituted and containing, in addition to carbon, independently, 1 to 3 optionally substituted moieties selected from the group consisting of NR₈, O, S, SO, and SO₂; R₈ is selected from the group consisting of alkyl, aryl, arylC₁₋₄alkyl, heteroaryl, heteroaryl C₁₋₄alkyl, heterocyclic, COOR₈, and a heterocyclic C₁₋₄alkyl moiety, all of which moieties may be optionally substituted;

m is an integer having a value of 1 to 3;

m' is 0, or an integer having a value of 1 or 2;

10 n is an integer having a value of 1 to 3;

q is 0, or an integer having a value of 1 to 10;

t is 0, or an integer having a value of 1 or 2;

s is an integer having a value of 1 to 3;

R₁ is independently selected from the group consisting of hydrogen, halogen, nitro, cyano, C₁₋₁₀ alkyl, halosubstituted C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₁₋₁₀ alkoxy, halosubstituted C₁₋₁₀alkoxy, azide, S(O)_tR₄, (CR₈R₈)_q S(O)_tR₄, hydroxy, hydroxy substituted C₁₋₄alkyl, aryl, aryl C₁₋₄ alkyl, aryl C₂₋₁₀ alkenyl, aryloxy, aryl C₁₋₄ alkyloxy, heteroaryl, heteroarylalkyl, heteroaryl C₂₋₁₀ alkenyl, heteroaryl C₁₋₄ alkyloxy, heterocyclic, heterocyclic C₁₋₄alkyl, heterocyclicC₁₋₄alkyloxy, heterocyclicC₂₋₁₀ alkenyl, (CR₈R₈)_q NR₄R₅, (CR₈R₈)_q C(O)NR₄R₅, C₂₋₁₀ alkenyl C(O)NR₄R₅, (CR₈R₈)_q C(O)NR₄R₁₀, S(O)₃R₈, (CR₈R₈)_q C(O)R₁₁, C₂₋₁₀ alkenyl C(O)R₁₁, C₂₋₁₀ alkenyl C(O)OR₁₁, (CR₈R₈)_q C(O)OR₁₁, (CR₈R₈)_q OC(O)R₁₁, (CR₈R₈)_q NR₄C(O)R₁₁, (CR₈R₈)_q C(NR₄)NR₄R₅, (CR₈R₈)_q NR₄C(NR₅)R₁₁, (CR₈R₈)_q NHS(O)₂R₁₃, and (CR₈R₈)_q S(O)₂NR₄R₅; or two R₁ moieties together may form O-(CH₂)_sO or a 5 to 6 membered saturated or unsaturated ring, such that the alkyl, aryl, arylalkyl, heteroaryl, or heterocyclic moieties may be optionally substituted;

R₄ and R₅ are independently selected from the group consisting of hydrogen, optionally substituted C₁₋₄ alkyl, optionally substituted aryl, optionally substituted aryl C₁₋₄alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C₁₋₄alkyl,

77 85

heterocyclic, and heterocyclicC₁₋₄ alkyl, or R₄ and R₅ together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O, N and S;

R₆ and R₇ are independently selected from the group consisting of hydrogen, a C₁₋₄ alkyl, heteroaryl, aryl, alkyl aryl, and alkyl C₁₋₄ heteroalkyl; or R₆ and R₇ together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom which is selected from the group consisting of oxygen, nitrogen or sulfur, and which ring may be optionally substituted;

Y is selected from the group consisting of furan, thiophene, pyrrole, oxazole, imidazole, thiazole, pyrazole, isooxazole, isothiazole, 1,2,3 or 1,2,4 oxadiazole, 1,2,3 or 1,2,4 triazole, 1,2,3 or 1,2,4 thiadiazole, pyridine, pyrimidine, pyridazine, pyrazine, 1,3,5, or 1,2,3 or 1,2,4 triazine, 1,2,4,5 tetrazine, indole, benzofuran, indazole, benzimidazole, benzothiazole, quinoline, isoquinoline, cinnoline, phthalazine, quinoxaline and quinoxaline all of which moieties can be substituted 1-3 times with R₁

R₈ is hydrogen or C₁₋₄ alkyl;

R₉ is hydrogen or a C₁₋₄ alkyl;

R₁₀ is C₁₋₁₀ alkyl C(O)₂R₈;

R₁₁ is selected from the group consisting of hydrogen, optionally substituted C₁₋₄ alkyl, optionally substituted aryl, optionally substituted aryl C₁₋₄alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC₁₋₄alkyl, optionally substituted heterocyclic, and optionally substituted heterocyclicC₁₋₄alkyl; and

R₁₃ is selected from the group consisting of C₁₋₄ alkyl, aryl, aryl C₁₋₄alkyl, heteroaryl, heteroarylC₁₋₄alkyl, heterocyclic, and heterocyclicC₁₋₄alkyl; or a pharmaceutically acceptable salt thereof.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of Formula (I), may also be used in association with the veterinary treatment of mammals, other than humans, in need of inhibition of IL-8 or other chemokines which bind to the IL-8 α and β receptors. Chemokine mediated

78 ~~8~~

diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted herein in the Methods of Treatment section.

Suitably, R_b is independently hydrogen, NR_6R_7 , OH, OR_a , C_{1-4} alkyl, aryl, aryl C_{1-4} alkyl, aryl C_{2-4} alkenyl, heteroaryl, heteroaryl C_{1-4} alkyl, heteroaryl C_{2-4} alkenyl, heterocyclic, heterocyclic C_{1-4} alkyl, or a heterocyclic C_{2-4} alkenyl moiety, all of which moieties may be optionally substituted one to three times independently by halogen, nitro, halosubstituted C_{1-4} alkyl, C_{1-4} alkyl, amino, mono or di- C_{1-4} alkyl substituted amine, cycloalkyl, cycloalkyl C_{1-5} alkyl, OR_a , $C(O)R_a$, $NR_aC(O)OR_a$, $OC(O)NR_6R_7$, aryloxy, aryl C_{1-4} oxy, hydroxy, C_{1-4} alkoxy, $NR_9C(O)R_a$, $S(O)_mR_a$, $C(O)NR_6R_7$, $C(O)OH$, $C(O)OR_a$, $S(O)_2NR_6R_7$, $NHS(O)_2R_a$. Alternatively; the two R_b substituents can join to form a 3-10 membered ring, optionally substituted and containing, in addition to carbon, independently, 1 to 3 NR_9 , O, S, SO, or SO_2 moieties which can be optionally substituted.

Suitably, R_a is an alkyl, aryl, aryl C_{1-4} alkyl, heteroaryl, heteroaryl C_{1-4} alkyl, heterocyclic, or a heterocyclic C_{1-4} alkyl moiety, all of which moieties may be optionally substituted.

Suitably, R_1 is independently selected from hydrogen; halogen; nitro; cyano; halosubstituted C_{1-10} alkyl, such as CF_3 , C_{1-10} alkyl, such as methyl, ethyl, isopropyl, or n-propyl, C_{2-10} alkenyl, C_{1-10} alkoxy, such as methoxy, or ethoxy; halosubstituted C_{1-10} alkoxy, such as trifluoromethoxy, azide, $(CR_gR_g)_q S(O)_tR_4$, wherein t is 0, 1 or 2, hydroxy, hydroxy C_{1-4} alkyl, such as methanol or ethanol, aryl, such as phenyl or naphthyl, aryl C_{1-4} alkyl, such as benzyl, aryloxy, such as phenoxy, aryl C_{1-4} alkyloxy, such as benzyloxy; heteroaryl, heteroarylalkyl, heteroaryl C_{1-4} alkyloxy; aryl C_{2-10} alkenyl, heteroaryl C_{2-10} alkenyl, heterocyclic C_{2-10} alkenyl, $(CR_gR_g)_qNR_4R_5$, C_{2-10} alkenyl $C(O)NR_4R_5$, $(CR_gR_g)_qC(O)NR_4R_5$, $(CR_gR_g)_qC(O)NR_4R_{10}$, $S(O)_3H$, $S(O)_3R_g$, $(CR_gR_g)_qC(O)R_{11}$, C_{2-10} alkenyl $C(O)R_{11}$, C_{2-10} alkenyl $C(O)OR_{11}$, $(CR_gR_g)_q C(O)R_{11}$, $(CR_gR_g)_qC(O)OR_{11}$, $(CR_gR_g)_q OC(O)R_{11}$, $(CR_gR_g)_qNR_4C(O)R_{11}$, $(CR_gR_g)_qC(NR_4)NR_4R_5$, $(CR_gR_g)_q NR_4C(NR_5)R_{11}$, $(CR_gR_g)_qNHS(O)_2R_{13}$, $(CR_gR_g)_qS(O)_2NR_4R_5$. All

60188410-031000

3

10

15

15

15

15

20

20

25

25

88 86

(CR₈R₈)_qC(NR₄)NR₄R₅; (CR₈R₈)_qNR₄C(NR₅)R₁₁; (CR₈R₈)_qNR₄C(O)R₁₁;
 (CR₈R₈)_qNHS(O)₂R₁₃; or (CR₈R₈)_qS(O)₂NR₄R₅; or two Y moieties together
 may form O-(CH₂)₅-O or a 5 to 6 membered saturated or unsaturated ring. The aryl,
 heteroaryl and heterocyclic containing moieties noted above may all be optionally
 5 substituted as defined herein.

Suitably s is an integer having a value of 1 to 3.

Suitably, R₂ is an alkyl, aryl C₁₋₄ alkyl, heteroaryl, heteroaryl-C₁₋₄alkyl,
 heterocyclic, or a heterocyclicC₁₋₄ alkyl, wherein all of these moieties may all be
 optionally substituted.

10 As used herein, "optionally substituted" unless specifically defined shall
 mean such groups as halogen, such as fluorine, chlorine, bromine or iodine,
 hydroxy; hydroxy substituted C₁₋₁₀alkyl, C₁₋₁₀ alkoxy, such as methoxy or ethoxy,
 S(O)_{m'}C₁₋₁₀ alkyl, wherein m' is 0, 1 or 2, such as methyl thio, methyl sulfinyl or
 methyl sulfonyl; amino, mono & di-substituted amino, such as in the NR₄R₅ group,
 15 NHC(O)R₄, C(O)NR₄R₅, C(O)OH, S(O)₂NR₄R₅, NHS(O)₂R₂₀, C₁₋₁₀ alkyl, such
 as methyl, ethyl, propyl, isopropyl, or t-butyl, halosubstituted C₁₋₁₀ alkyl, such
 CF₃, an optionally substituted aryl, such as phenyl, or an optionally substituted
 arylalkyl, such as benzyl or phenethyl, optionally substituted heterocyclic, optionally
 substituted heterocyclicalkyl, optionally substituted heteroaryl, optionally
 20 substituted heteroaryl alkyl, wherein these aryl, heteroaryl, or heterocyclic moieties
 may be substituted one to two times by halogen; hydroxy; hydroxy substituted alkyl,
 C₁₋₁₀ alkoxy; S(O)_mC₁₋₁₀ alkyl; amino, mono & di-substituted alkyl amino, such
 as in the NR₄R₅ group; C₁₋₁₀ alkyl, or halosubstituted C₁₋₁₀ alkyl, such as CF₃.

R₂₀ is suitably C₁₋₄ alkyl, aryl, aryl C₁₋₄alkyl, heteroaryl,
 25 heteroarylC₁₋₄alkyl, heterocyclic, or heterocyclicC₁₋₄alkyl.

Suitable pharmaceutically acceptable salts are well known to those skilled in
 the art and include basic salts of inorganic and organic acids, such as hydrochloric
 acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphononic acid,
 ethane sulphononic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid,
 30 oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid,
 phenylacetic acid and mandelic acid. In addition, pharmaceutically acceptable salts

50188410-031000

81 82

of compounds of Formula (I) may also be formed with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations.

5 The following terms, as used herein, refer to:

- "halo" - all halogens, that is chloro, fluoro, bromo and iodo.
- "C₁₋₁₀alkyl" or "alkyl" - both straight and branched chain moieties of 1 to

10 10 carbon atoms, unless the chain length is otherwise limited, including, but not limited to, methyl, ethyl, *n*-propyl, *iso*-propyl, *n*-butyl, *sec*-butyl, *iso*-butyl, *tert*-butyl, *n*-pentyl and the like.

- "cycloalkyl" is used herein to mean cyclic moiety, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like.

15 • "alkenyl" is used herein at all occurrences to mean straight or branched chain moiety of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl and the like.

- "aryl" - phenyl and naphthyl;

20 • "heteroaryl" (on its own or in any combination, such as "heteroaryloxy", or "heteroaryl alkyl") - a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan, thiophene, quinoline, isoquinoline, quinoxaline, pyridine, pyrimidine, oxazole, tetrazole, thiazole, thiadiazole, triazole, imidazole, or benzimidazole.

25 • "heterocyclic" (on its own or in any combination, such as "heterocyclicalkyl") - a saturated or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, tetrahydropyran, thiomorpholine, or
30 imidazolidine. Furthermore, sulfur may be optionally oxidized to the sulfone or the sulfoxide.

00000-0188105

82 88

• "arylalkyl" or "heteroarylalkyl" or "heterocyclicalkyl" is used herein to mean C₁₋₁₀ alkyl, as defined above, attached to an aryl, heteroaryl or heterocyclic moiety, as also defined herein, unless otherwise indicated.

• "sulfinyl" - the oxide S (O) of the corresponding sulfide, the term "thio" refers to the sulfide, and the term "sulfonyl" refers to the fully oxidized S(O)₂ moiety.

• "wherein two R₁ moieties may together form a 5 or 6 membered saturated or unsaturated ring" is used herein to mean the formation of an aromatic ring system, such as naphthalene, or is a phenyl moiety having attached a 6 membered partially saturated or unsaturated ring such as a C₆ cycloalkenyl, i.e. hexene, or a C₅ cycloalkenyl moiety, such as cyclopentene.

Illustrative compounds of Formula (I) include:

N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(pyridin-2-yl)urea;
 N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(2-chloro-pyridin-3-yl)urea;
 15 N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(1-phenyl-1H-1,2,3-triazol-5-yl)urea;
 N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(1,3-dimethylpyrazol-5-yl)urea;
 N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(1-methylpyrazol-5-yl)urea; and
 N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(2-methyl-pyridin-3-yl)urea.

20 METHODS OF PREPARATION


The compounds of Formula (I) may be obtained by applying synthetic procedures, some of which are illustrated in the Schemes below. The synthesis provided for in these Schemes is applicable for the producing compounds of Formulas (I) having a variety of different R, R₁, and Z groups which are reacted, employing optional substituents which are suitably protected, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed. Once the urea nucleus has been established, further compounds of these formulas may be prepared by applying standard techniques for functional group interconversion, well known in the art.

10

50188410-031000

EB BH

Scheme 1



5


a) i) NCS, AcOH, H₂O ii) NaOH MeOH b) H₂SO₄, HNO₃ c) NaOH MeOH d) POCl₃, POC_l₃ e) HNR₂R', Et₃N, CH₂Cl₂

The route to the 2,4 dichloro sulfonamide 5-scheme 1 is outlined above, wherein the commercially available 2,6-dichloro thiol can be oxidized to the sulfonyl halide using a halogenating agent such as NCS, NBS, chlorine or bromine in the presence of a protic solvent such as alcohol, acetic acid or water. The sulfonyl halide can be hydrolyzed by using a metal hydroxide such as sodium or potassium hydroxide to form the corresponding sulfonic acid salt. The sulfonic acid salt can then be nitrated under nitration conditions such as nitric acid in a solvent of strong acid such as sulfuric acid to form the nitro phenyl sulfonic acid 3-scheme 1. The sulfonic acid 3-scheme 1 can be converted to the sulfonamide 5-scheme 1 using a three step procedure involving the formation of the metal salt using a base such as sodium hydroxide, sodium hydride or sodium carbonate to form 4-scheme 1. The sulfonic acid salt is then converted to the sulfonyl chloride using POCl₃ with POC_l₃ as a solvent. The sulfonyl chloride can then be converted to the corresponding sulfonamide using the desired amine HNR₂R' in a non-protic solvent such as CH₂Cl₂ using a base such as triethyl amine at temperatures ranging from -78 °C to 60 °C to form the corresponding sulfonamide 5-scheme 3. This method is not limited to the 2,6-dichlorophenyl thiol it can also be applied to the 2,6-

84 96

difluorophenyl thiol, 2,6-dibromophenyl thiol and the 2,6-diiodophenyl thiol. The halogens in these compounds can be converted to the corresponding cyano, amino, thiol, or alkoxy compounds by nucleophilic displacement reactions using nucleophiles such as alkyl thiolates, alkoxides, amine and cyanides. The halogens can also be further functionalized by palladium coupling and carbonylation reactions, well known in the art, to form the corresponding amido, carbonyl, alkenyl, alkyl, phenyl and heterocyclic substituted products as required by Formula (1).

The ortho chloride can be selectively hydrolyzed by using a hydroxide base in a protic or non protic solvent or by in situ generation of hydroxide by the use of NaH and water in a non protic solvent such as THF to form 2-scheme 2. The nitro can then be reduced using a number of reduced agents such as palladium on carbon and hydrogen, tin chloride, iron, rhodium or sodium sulfite to form the desired aniline 3-scheme 2.



a) NaH, H₂O, THF b) Pd/C, H₂, EtOAc


The urea can be formed by coupling the heterocyclic isocyanate with desired hydroxyaniline. If the desired heterocyclic isocyanate is unstable like the 2-pyridyl isocyanate, the isocyanate is generated in the presence of hydroxyaniline by premixing the acylazide with hydroxy aniline and trapping the heterocyclic isocyanate in situ. The acyl azide can be generated by treating the carboxy heterocycle with DPPA or by a two step procedure involving formation of the acid halide or mixed anhydride followed by attack with an azide salt such as sodium azide. If the isocyanate is stable then the isocyanate can be formed by reaction of the corresponding heterocyclic amine with triphosgene.

22

00070-0188109

85 41

Scheme 3




a) EtOCOCN, Et₃N, acetone/water b) NaN₃ c) DMF

Alternatively the isocyanate can be formed on the other side of the urea by first protecting the hydroxyl using a standard protecting group such as TBS to form 2 scheme 4. The protected hydroxy aniline is then converted to the isocyanate using standard conditions such as treatment with triphosgene in the presence of a base such as triethyl amine or sodium bicarbonate to form 3 scheme 4. The isocyanate is then coupled with heterocyclic amine to form the corresponding urea followed by deprotection of the phenol group using standard procedures to form the desired compound 4 scheme 4.

86 92

Scheme 4



a) TBSCl, imid, CH_2Cl_2 b) triphosgene, Et_3N , CH_2Cl_2 c) DMF d) TBAF,

CH_2Cl_2

SYNTHETIC EXAMPLES

The invention will now be described by reference to the following examples, which are merely illustrative and are not to be construed as a limitation of the scope of the present invention. All temperatures are given in degrees centigrade, all solvents are highest available purity and all reactions run under anhydrous conditions in an argon atmosphere unless otherwise indicated.

In the Examples, all temperatures are in degrees Centigrade ($^{\circ}\text{C}$). Mass spectra were performed upon a VG Zab mass spectrometer using fast atom bombardment, unless otherwise indicated. ^1H -NMR (hereinafter "NMR") spectra were recorded at 250 MHz using a Bruker AM 250 or Am 400 spectrometer. Multiplicities indicated are: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet and br indicates a broad signal. Sat. indicates a saturated solution, eq indicates the proportion of a molar equivalent of reagent relative to the principal reactant.

General Method:

Synthesis of 3-(aminosulfonyl)-4-chloro-2-hydroxy aniline.

a) 2,6-Dichlorobenzenesulfonyl chloride

24

50188410-031000

43
87

Into a mixture of 200 milliliters (hereinafter "mL") of acetic acid, water and dichloromethane (3/1/4, v/v/v), 2,6-dichlorobenzenethiol (10.0 grams (hereinafter "g"), 55.8 millimoles (hereinafter "mmol"), N-chlorosuccinimide (37.28 g, 279 mmol) and potassium acetate (2.29 g, 27.9 mmol) were added. The resulting mixture was stirred at 0°C, then warmed to room temperature overnight. The mixture was then diluted with 200 mL of dichloromethane, and washed with water (100 mL x 3). The organic layer was dried (Na₂SO₄) and concentrated to give the desired product (11 g, 80%). ¹H NMR (CDCl₃): δ 7.57 (d, 2H), 7.47 (t, 1H). 2,6-Dichloro-3-nitrobenzenesulfonic acid. Lithium hydroxide hydrate (12.64g, 0.301mol) was added to a solution of 2,6-dichlorobenzenesulfonyl chloride (35.53g, 0.146mol) in MeOH (600mL) and the reaction was allowed to stir at room temperature for 3 hr. The reaction mixture was filtered to remove suspended solids and then concentrated. The resulting solid was dried *in vacuo* overnight to remove any residual MeOH. The solid was then dissolved in H₂SO₄ (300mL) and chilled in an ice bath. A solution of H₂SO₄ (35mL) and HNO₃ (13.2mL) was slowly added to the above reaction over 90 min. The reaction was allowed to warm up to room temperature overnight and then slowly poured into ice water (1200mL) and extracted with EtOAc. The combined organic layers were dried (MgSO₄) and concentrated to yield 2,6-dichloro-3-nitrobenzenesulfonic acid (44.35g, 99%) as the dihydrate. EI-MS (m/z) 270 (M-H)⁺.

b) 2,6-Dichloro-3-nitrobenzenesulfonyl chloride

Potassium hydroxide (12.07g, 0.215mol) was added to a solution of 2,6-dichloro-3-nitrobenzenesulfonic acid dihydrate (44.35g, 0.144mol) in MeOH (850mL) and the reaction was allowed to stir at room temperature for 14 hr. The reaction mixture was concentrated and the resulting solid was dried *in vacuo* overnight. To this was added PCl₅ (30.00g, 0.144mol) followed by POCl₃ (475mL) and the mixture was refluxed overnight. The reaction was then cooled to room temperature and concentrated. The resulting mixture was taken up in EtOAc and chilled in an ice bath. Ice chunks were slowly added to the reaction mixture to quench any leftover PCl₅. When bubbling ceased, water was added and the reaction mix was extracted with EtOAc. The

BB GH

organic layer was dried (MgSO_4) and concentrated to yield 2,6-Dichloro-3-nitrobenzenesulfonyl chloride (40.42g, 97%). ^1H NMR ($\text{DMSO}-d_6$) δ 7.88 (d, 1H), 7.75 (d, 1H).

5 c) 2,6-dichloro-3-nitrobenzenesulfonamide

Into a solution of 2,6-dichloro-3-nitrobenzenesulfonyl chloride (9.48g, 32.6mmol) in 105 mL of dichloromethane at -78°C was bubbled ammonia gas for 6 hours. The mixture was warmed to room temperature and acidified to $\text{pH} > 1$ with 6N aq. HCl, then extracted with ethyl acetate. The combined organic layer was then concentrated to give the crude material. Column chromatography on silica gel, eluting with ethyl acetate/hexane (50/50, v/v), gave the desired product (6.30g, 71%). ^1H NMR ($\text{DMSO}-d_6$): δ 8.26 (s, 2H), 8.20 (d, 1H), 7.92 (d, 1H).

d) 6-chloro-2-hydroxy-3-nitrobenzenesulfonamide


15 A mixture of 2,6-dichloro-3-nitrobenzenesulfonamide (2.61 g, 9.64 mmol), 60% sodium hydride (1.15g, 28.9 mmol) and water (174 μL , 9.64 mmol) was heated to 45°C while kept at argon atmosphere for 3 days. The reaction was monitored by ^1H NMR. 0.1 equivalent water was added to the mixture when the reaction was not completed. The solvent was evaporated when the reaction almost completed indicated by ^1H NMR. The residue was diluted with ethyl acetate and washed with 1N aq. HCl. The solvent was concentrated to give the crude material. Column chromatography on silica gel, eluting with ethyl acetate/hexane/acetic acid (50/48/2, v/v/v), gave the desired product (1.87g, 77%). EI-MS (m/z) 250.84, 252.89 (M).

25 e) 3-amino-6-chloro-2-hydroxybenzenesulfonamide

To a solution of 6-chloro-2-hydroxy-3-nitrobenzenesulfonamide (3 g, 11.9 mmol) in ethyl acetate, was added 10% Pd/C (1.24g). The mixture was flushed with argon, and then stirred on Parr apparatus at 40psi for 25 min at room temperature. The mixture was filtered through celite and the celite was washed with methanol. The solvent was evaporated to give the desired product (2.51g, 95%). EI-MS (m/z) 222.75, 224.74 (M).

26

6018410-031000

89 **Example 1****Preparation of N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(pyridin-2-yl)urea****a) 2-(azidocarbonyl)-pyridine**

- 5 To a solution of picolinic acid (1.0 g, 8.12 mmol) in a mixture of acetone (10 mL) and water (3 mL) was added triethylamine (1.7 mL, 12.2 mmol). The mixture was cooled to 0°C in a ice-bath. Ethylchloroformate (1.32 g, 12.2 mmol) was then added and the resulting mixture was stirred for 1.5 hours at 0°C. To the mixture was added sodium azide (0.844 g, 13.0 mmol), and the mixture was stirred for another 1.5 hours.
- 10 The mixture was concentrated, the residue was diluted with dichloromethane and washed with water. The organic layer was dried over MgSO₄ and concentrated to give desired product (817 mg, 68%). ¹H NMR (CDCl₃) (δ) 8.74 (d, 1H), 8.15 (d, 1H), 7.88 (m, 1H), 7.55 (m, 1H).
- 15 b) N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(pyridin-2-yl)urea
Under Argon, a solution of 3-amino-6-chloro-2-hydroxybenzenesulfonamide (300 mg, 1.35 mmol) and 2-(azidocarbonyl)-pyridine (400 mg, 2.70 mmol) in 5 mL of N,N-dimethyl-formamide was heated to 80°C for 2 hours. The mixture was kept at room temperature for another 20 hours. Purification upon Gilson HPLC, eluting
- 20 with acetonitrile/water (10/90, v/v to 90/10, v/v, over 10 min), gave the desired product (287 mg, 62%). LC-MS (m/z) 343.0 (M⁺).

Example 2**Preparation of N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(2-chloro-pyridin-3-yl)urea****a) 3-(azidocarbonyl)-2-chloropyridine**

- To a solution of 2-chloronicotinic acid (1.0 g, 6.35 mmol) in a mixture of acetone (14 mL) and water (6 mL) was added triethylamine (0.97 mL, 6.98 mmol). The
- 30 mixture was cooled to 0°C in a ice-bath. Ethylchloroformate (1.03 g, 9.5 mmol) was then added and the resulting mixture was stirred for 1.0 hour at 0°C. To the mixture

22

00188410-031000

90 46

was added sodium azide (0.70g, 10.8mmol), and the mixture was stirred for another 3 hours. The mixture was concentrated, the residue was diluted with dichloromethane and washed with water. The organic layer was dried over MgSO₄ and concentrated to give desired product (550mg, 48%). ¹HNMR (CDCl₃) (δ) 8.57 (d, 1H), 8.22 (d, 1H), 7.37 (t, 1H).

b) N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(2-chloro-pyridin-3-yl)urea
Under Ar, a solution of 3-amino-6-chloro-2-hydroxybenzenesulfonamide (50mg, 0.22mmol) and 3-(azidocarbonyl)-2-chloropyridine (123mg, 0.67mmol) in 1 mL of N,N-dimethyl-formamide was stirred at room temperature for 3 days. Purification upon Gilson HPLC, eluting with acetonitrile/ water (10/90, v/v to 90/10, v/v, over 10min), gave the desired product (15mg, 18%). LC-MS (m/z) 377.0 (M⁺).

Example 3

15 Preparation of N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(1-phenyl-1H-1,2,3-triazol-5-yl)urea

a) 5-(azidocarbonyl)-1-phenyl-1H-1,2,3-triazole
To a solution of 1-phenyl-1H-1,2,3-triazole-5-carboxylic acid (500mg, 2.64mmol) in a mixture of acetone (10 mL) and water (5 mL) was added triethylamine (0.55mL, 3.96mmol). The mixture was cooled to 0°C in a ice-bath. Ethylchloroformate (573mg, 5.28 mmol) was then added and the resulting mixture was stirred for 1.5 hours at 0°C. To the mixture was added sodium azide (0.844g, 13.0mmol), and the mixture was stirred for another 1.5hours. The mixture was concentrated, the residue was diluted with dichloromethane and washed with water. The organic layer was dried over MgSO₄ and concentrated to give desired product (100mg, 18%).
¹HNMR (CDCl₃) (δ) 8.30 (s, 1H), 7.57 (t, 3H), 7.51 (d, 2H).

b) N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(1-phenyl-1H-1,2,3-triazol-5-yl)urea

28

/ 60188410-031000

91


Under Ar, a solution of 3-amino-6-chloro-2-hydroxybenzenesulfonamide (104mg, 0.46mmol) and 5-(azidocarbonyl)-1-phenyl-1H-1,2,3-triazole (100mg, 0.46mmol) in 5 mL of N,N-dimethyl-formamide was stirred at room temperature for 3 days. Purification upon Gilson HPLC twice, eluting with acetonitrile/ water (10/90, v/v to 90/10, v/v, over 10min), gave the desired product (2.7mg, 1.4%). LC-MS (m/z) 409.9 (M⁺).

Example 4

Preparation of N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(1,3-dimethylpyrazol-5-yl)urea

10

a) 5-(azidocarbonyl)-1,3-dimethylpyrazole

To a solution of 1,3-dimethylpyrazol-5-carboxylic acid (500mg, 3.57 mmol) in a mixture of acetone (10 mL) and water (5 mL) was added triethylamine (0.75mL, 7.13mmol). The mixture was cooled to 0°C in a ice-bath. Ethylchloroformate (774mg, 7.13mmol) was then added and the resulting mixture was stirred for 1.5 hours at 0°C. To the mixture was added sodium azide (0.844g, 13.0mmol), and the mixture was stirred for another 1.5hours. The mixture was concentrated, the residue was diluted with dichloromethane and washed with water. The organic layer was dried over MgSO₄ and concentrated to give desired product (203mg, 34%).

20

¹HNMR (CDCl₃) (δ) 6.60 (s, 1H), 4.11 (s, 3H), 2.25 (s, 3H).

b) N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(1,3-dimethylpyrazol-5-yl)urea

Under Ar, a solution of 3-amino-6-chloro-2-hydroxybenzenesulfonamide (137mg, 0.61mmol) and 5-(azidocarbonyl)-1,3-dimethylpyrazole (203mg, 1.23mmol) in 2 mL of N,N-dimethyl-formamide was stirred at room temperature for 3 days. Purification upon Gilson HPLC, eluting with acetonitrile/ water (10/90, v/v to 90/10, v/v, over 10min), gave the desired product (17mg, 7.7%). LC-MS (m/z) 360.2 (M⁺).

29

60188410-031000

92 98

Example 5**Preparation of N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(1-methylpyrazol-5-yl)urea****5 a) 5-(azidocarbonyl)-1-methylpyrazole**

To a solution of 1-methylpyrazol-5-carboxylic acid (500mg, 3.96 mmol) in a mixture of acetone (6.6 mL) and water (3.3 mL) was added triethylamine (0.83mL, 5.94mmol). The mixture was cooled to 0°C in a ice-bath. Ethylchloroformate (774mg, 7.13mmol) was then added and the resulting mixture was stirred for 1.5
10 hours at 0°C. To the mixture was added sodium azide (0.52g, 7.92mmol), and the mixture was stirred for another 2 hours. The mixture was concentrated, the residue was diluted with dichloromethane and washed with water. The organic layer was dried over MgSO₄ and concentrated to give desired product (280mg, 47%).

¹HNMR (CDCl₃) (δ) 7.48 (s, 1H), 6.86 (s, 1H), 4.21 (s, 3H).

15

b) N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(1-methylpyrazol-5-yl)urea

Under Ar, a solution of 3-amino-6-chloro-2-hydroxybenzenesulfonamide (100mg, 0.45mmol) and 5-(azidocarbonyl)-1-methylpyrazol (280mg, 1.85mmol) in 2 mL of N,N-dimethyl-formamide was stirred at room temperature for 3 days. Purification
20 upon Gilson HPLC, eluting with acetonitrile/ water (10/90, v/v to 90/10, v/v, over 10min), gave the desired product (12mg, 7.7%). LC-MS (m/z) 346.0 (M⁺).

Example 6**Preparation of N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(2-methylpyridin-3-yl)urea**

25

a) 3-(azidocarbonyl)-2-methylpyridine

To a solution of 2-methylnicotinic acid (500mg, 3.65 mmol) in a mixture of acetone (6.6 mL) and water (3.3 mL) was added triethylamine (1.02 mL, 7.3mmol). The
30 mixture was cooled to 0°C in a ice-bath. Ethylchloroformate (0.79g, 7.3mmol) was then added and the resulting mixture was stirred for 1.5 hours at 0°C. To the

30

60188410-031000

93
24

mixture was added sodium azide (0.47g, 7.3mmol), and the mixture was stirred for another 1.5 hours. The mixture was concentrated, the residue was diluted with dichloromethane and washed with water. The organic layer was dried over MgSO₄ and concentrated to give desired product (390mg, 62%). ¹HNMR (CDCl₃) (δ) 8.67 (d, 1H), 8.21 (d, 1H), 7.24 (t, 1H), 2.88 (s, 3H).

b) *N*-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-*N'*-(2-methyl-pyridin-3-yl)urea
Under Ar, a solution of 3-amino-6-chloro-2-hydroxybenzenesulfonamide (64mg, 0.29mmol) and 3-(azidocarbonyl)-2-methylpyridine (390mg, 2.41mmol) in 1 mL of *N,N*-dimethyl-formamide was stirred at room temperature for 20 hours. Purification upon Gilson HPLC, eluting with acetonitrile/ water (10/90, v/v to 90/10, v/v, over 10min), gave the desired product (32mg, 31%). LC-MS (*m/z*) 357.0 (*M*⁺).

Example 7

15 Preparation of *N*-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-*N'*-(3,5-dimethylisoxazol-4-yl)urea

a) *N*-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-*N'*-(3,5-dimethylisoxazol-4-yl)urea
20 Under Ar, a solution of 3-amino-6-chloro-2-hydroxybenzenesulfonamide (50mg, 0.23mmol) and 3,5-dimethylisoxazol-4-yl isocyanate (31mg, 0.23mmol) in 1.0 mL of *N,N*-dimethyl-formamide was stirred at room temperature for 20 hours. Purification upon Gilson HPLC, eluting with acetonitrile/water (10/90, v/v to 90/10, v/v, over 10min), gave the desired product (40mg, 49%). LC-MS (*m/z*) 361.0 (*M*⁺).

25 METHOD OF TREATMENT

The compounds of Formula (I), or a pharmaceutically acceptable salt thereof can be used in the manufacture of a medicine for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated IL-8 cytokine production by such mammal's cell, such as but not limited to monocytes and/or macrophages, or other chemokines

94
~~88~~

which bind to the IL-8 α or β receptor, also referred to as the type I or type II receptor.

Accordingly, the present invention provides a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 α or β receptor and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In particular, the chemokines are IL-8, GRO α , GRO β , GRO γ , NAP-2 or ENA-78.

The compounds of Formula (I) are administered in an amount sufficient to inhibit cytokine function, in particular IL-8, GRO α , GRO β , GRO γ , NAP-2 or ENA-78, such that they are biologically regulated down to normal levels of physiological function, or in some case to subnormal levels, so as to ameliorate the disease state. Abnormal levels of IL-8, GRO α , GRO β , GRO γ , NAP-2 or ENA-78 for instance in the context of the present invention, constitute: (i) levels of free IL-8 greater than or equal to 1 picogram per mL; (ii) any cell associated IL-8, GRO α , GRO β , GRO γ , NAP-2 or ENA-78 above normal physiological levels; or (iii) the presence of IL-8, GRO α , GRO β , GRO γ , NAP-2 or ENA-78 above basal levels in cells or tissues in which IL-8, GRO α , GRO β , GRO γ , NAP-2 or ENA-78 respectively, is produced.

The compounds of Formula (I), in generally have been shown to have a longer $t_{1/2}$ and improved oral bioavailability over the compounds disclosed in WO 96/25157 and WO 97/29743 whose disclosures are incorporated herein by reference.

There are many disease states in which excessive or unregulated IL-8 production is implicated in exacerbating and/or causing the disease. Chemokine mediated diseases include psoriasis, atopic dermatitis, osteo arthritis, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock, multiple sclerosis, endotoxic shock, gram negative sepsis, toxic shock syndrome, cardiac and renal reperfusion injury, glomerulonephritis, thrombosis, graft vs. host reaction, Alzheimer's disease, allograft rejections, malaria, restenosis, angiogenesis, atherosclerosis, osteoporosis, gingivitis and undesired hematopoietic stem cells release and diseases caused by respiratory viruses, herpes viruses, and hepatitis viruses, meningitis, cystic fibrosis, pre-term labor, cough, pruritus, multi-

32

000100-01488709

95
10/

organ dysfunction, trauma, strains, sprains, contusions, psoriatic arthritis, herpes, encephalitis, CNS vasculitis, traumatic brain injury, CNS tumors, subarachnoid hemorrhage, post surgical trauma, interstitial pneumonitis, hypersensitivity, crystal induced arthritis, acute and chronic pancreatitis, acute alcoholic hepatitis,

5 necrotizing enterocolitis, chronic sinusitis, uveitis, polymyositis, vasculitis, acne, gastric and duodenal ulcers, celiac disease, esophagitis, glossitis, airflow obstruction, airway hyperresponsiveness, bronchiolitis obliterans organizing pneumonia, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, cor pulmonale, dyspnea, emphysema, hypercapnea, hyperinflation, hypoxemia,

10 hyperoxia-induced inflammations, hypoxia, surgical lung volume reduction, pulmonary fibrosis, pulmonary hypertension, right ventricular hypertrophy, sarcoidosis, small airway disease, ventilation-perfusion mismatching, wheeze, colds and lupus.

These diseases are primarily characterized by massive neutrophil infiltration,

15 T-cell infiltration, or neovascular growth, and are associated with increased IL-8, GRO α , GRO β , GRO γ , NAP-2 or ENA-78 production which is responsible for the chemotaxis of neutrophils into the inflammatory site or the directional growth of endothelial cells. In contrast to other inflammatory cytokines (IL-1, TNF, and IL-6), IL-8, GRO α , GRO β , GRO γ , NAP-2 or ENA-78 have the unique property of

20 promoting neutrophil chemotaxis, enzyme release including but not limited to elastase release as well as superoxide production and activation. The α -chemokines but particularly, GRO α , GRO β , GRO γ , NAP-2 or ENA-78, working through the IL-8 type I or II receptor can promote the neovascularization of tumors by promoting the directional growth of endothelial cells. Therefore, the inhibition of IL-8 induced

25 chemotaxis or activation would lead to a direct reduction in the neutrophil infiltration.

Recent evidence also implicates the role of chemokines in the treatment of HIV infections, Littleman *et al.*, Nature 381, pp. 661 (1996) and Koup *et al.*, Nature 381, pp. 667 (1996).

30 Present evidence also indicates the use of IL-8 inhibitors in the treatment of atherosclerosis. The first reference, Boisvert *et al.*, J. Clin. Invest. 1998, 101:353-363 shows, through bone marrow transplantation, that the absence of IL-8 receptors

96 102

on stem cells (and, therefore, on monocytes/macrophages) leads to a reduction in the development of atherosclerotic plaques in LDL receptor deficient mice. Additional supporting references are: Apostolopoulos, et al., Arterioscler. Thromb. Vasc. Biol. 1996, 16:1007-1012; Liu, et al., Arterioscler. Thromb. Vasc. Biol. 1997, 17:317-323; Rus, et al., Atherosclerosis, 1996, 127:263-271.; Wang et al., J. Biol. Chem. 1996, 271:8837-8842; Yue, et al., Eur. J. Pharmacol. 1993, 240:81-84; Koch, et al., Am. J. Pathol., 1993, 142:1423-1431.; Lee, et al., Immunol. Lett., 1996, 53, 109-113.; and Terkeltaub et al., Arterioscler. Thromb., 1994, 14:47-53.

The present invention also provides for a means of treating, in an acute setting, as well as preventing, in those individuals deemed susceptible to, CNS injuries by the chemokine receptor antagonist compounds of Formula (I).

CNS injuries as defined herein include both open or penetrating head trauma, such as by surgery, or a closed head trauma injury, such as by an injury to the head region. Also included within this definition is ischemic stroke, particularly to the brain area.

Ischemic stroke may be defined as a focal neurologic disorder that results from insufficient blood supply to a particular brain area, usually as a consequence of an embolus, thrombi, or local atheromatous closure of the blood vessel. The role of inflammatory cytokines in this area has been emerging and the present invention provides a mean for the potential treatment of these injuries. Relatively little treatment, for an acute injury such as these has been available.

TNF- α is a cytokine with proinflammatory actions, including endothelial leukocyte adhesion molecule expression. Leukocytes infiltrate into ischemic brain lesions and hence compounds which inhibit or decrease levels of TNF would be useful for treatment of ischemic brain injury. See Liu *et al.*, Stroke, Vol. 25., No. 7, pp. 1481-88 (1994) whose disclosure is incorporated herein by reference.

Models of closed head injuries and treatment with mixed 5-LO/CO agents is discussed in Shohami *et al.*, J. of Vasc. & Clinical Physiology and Pharmacology, Vol. 3, No. 2, pp. 99-107 (1992) whose disclosure is incorporated herein by reference. Treatment, which reduced edema formation, was found to improve functional outcome in those animals treated.

00188410.031000

97
103

The compounds of Formula (I) are administered in an amount sufficient to inhibit IL-8, binding to the IL-8 alpha or beta receptors, from binding to these receptors, such as evidenced by a reduction in neutrophil chemotaxis and activation. The discovery that the compounds of Formula (I) are inhibitors of IL-8 binding is based upon the effects of the compounds of Formulas (I) in the *in vitro* receptor binding assays which are described herein. The compounds of Formula (I) have been shown to be inhibitors of type II IL-8 receptors.

As used herein, the term "IL-8 mediated disease or disease state" refers to any and all disease states in which IL-8, GRO α , GRO β , GRO γ , NAP-2 or ENA-78 plays a role, either by production of IL-8, GRO α , GRO β , GRO γ , NAP-2 or ENA-78 themselves, or by IL-8, GRO α , GRO β , GRO γ , NAP-2 or ENA-78 causing another monokine to be released, such as but not limited to IL-1, IL-6 or TNF. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to IL-8, would therefore be considered a disease state mediated by IL-8.

As used herein, the term "chemokine mediated disease or disease state" refers to any and all disease states in which a chemokine which binds to an IL-8 α or β receptor plays a role, such as but not limited to IL-8, GRO- α , GRO- β , GRO γ , NAP-2 or ENA-78. This would include a disease state in which, IL-8 plays a role, either by production of IL-8 itself, or by IL-8 causing another monokine to be released, such as but not limited to IL-1, IL-6 or TNF. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to IL-8, would therefore be considered a disease stated mediated by IL-8.

As used herein, the term "cytokine" refers to any secreted polypeptide that affects the functions of cells and is a molecule, which modulates interactions between cells in the immune, inflammatory or hematopoietic response. A cytokine includes, but is not limited to, monokines and lymphokines, regardless of which cells produce them. For instance, a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte. Many other cells however also produce monokines, such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone

35

50188410 "0310 0

98
104

marrow stromal cells, epidermal keratinocytes and B-lymphocytes. Lymphokines are generally referred to as being produced by lymphocyte cells. Examples of cytokines include, but are not limited to, Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor-alpha (TNF- α) and Tumor Necrosis Factor beta (TNF- β).

As used herein, the term "chemokine" refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response, similar to the term "cytokine" above. A chemokine is primarily secreted through cell transmembranes and causes chemotaxis and activation of specific white blood cells and leukocytes, neutrophils, monocytes, macrophages, T-cells, B-cells, endothelial cells and smooth muscle cells. Examples of chemokines include, but are not limited to IL-8, GRO- α , GRO- β , GRO- γ , NAP-2, ENA-78, IP-10, MIP-1 α , MIP- β , PF4, and MCP 1, 2, and 3.

In order to use a compound of Formula (I) or a pharmaceutically acceptable salt thereof in therapy, it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice. This invention, therefore, also relates to a pharmaceutical composition comprising an effective, non-toxic amount of a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent.

Compounds of Formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions incorporating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation. The compounds of Formula (I) may be administered in conventional dosage forms prepared by combining a compound of Formula (I) with standard pharmaceutical carriers according to conventional procedures. The compounds of Formula (I) may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable character or diluent is dictated by the amount of active ingredient with which it is to be

36

00010-01488109

99
105

combined, the route of administration and other well-known variables. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.

A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25mg to about 1g. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.

Compounds of Formula (I) may be administered topically, that is by non-systemic administration. This includes the application of a compound of Formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, for instance from 1% to 2% by weight of the Formulation. It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0.1% to 1% w/w of the Formulation.

Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution

32

00000-01488109

100
106

optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.

Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as siliceous silicas, and other ingredients such as lanolin, may also be included.

Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container, which is then sealed and sterilized by autoclaving, or maintaining at 98-100°C for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.

Compounds of formula (I) may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or

38

50188410-031000

101
167

intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques. Compounds of Formula (I) may also be administered by inhalation that is by intranasal and oral
5 inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.

For all methods of use disclosed herein for the compounds of Formula (I) the daily oral dosage regimen will preferably be from about 0.01 to about 80 mg/kg of
10 total body weight. The daily parenteral dosage regimen about 0.001 to about 80 mg/kg of total body weight. The daily topical dosage regimen will preferably be from 0.1 mg to 150 mg, administered one to four, preferably two or three times daily. The daily inhalation dosage regimen will preferably be from about 0.01 mg/kg to about 1 mg/kg per day. It will also be recognized by one of skill in the art
15 that the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill
20 in the art that the optimal course of treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.

The invention will now be described by reference to the following biological
25 examples, which are merely illustrative and are not to be construed as a limitation of the scope of the present invention.

BIOLOGICAL EXAMPLES

The IL-8, and GRO- α chemokine inhibitory effects of compounds of the present invention are determined by the following *in vitro* assay:

30 Receptor Binding Assays:

[¹²⁵I] IL-8 (human recombinant) is obtained from Amersham Corp., Arlington Heights, IL, with specific activity 2000 Ci/mmol. GRO- α is obtained from

102
100

NEN- New England Nuclear. All other chemicals are of analytical grade. High levels of recombinant human IL-8 type α and β receptors were individually expressed in Chinese hamster ovary cells as described previously (Holmes, *et al.*, Science, 1991, 253, 1278). The Chinese hamster ovary membranes were

5 homogenized according to a previously described protocol (Haour, *et al.*, J. Biol. Chem., 249 pp 2195-2205 (1974)). Except that the homogenization buffer is changed to 10mM Tris-HCl, 1mM MgSO₄, 0.5mM EDTA (ethylene-diaminetetraacetic acid), 1mM PMSF (α -toluenesulphonyl fluoride), 0.5 mg/L Leupeptin, pH 7.5. Membrane protein concentration is determined using Pierce Co. micro-assay kit

10 using bovine serum albumin as a standard. All assays are performed in a 96-well micro plate format. Each reaction mixture contains ¹²⁵I IL-8 (0.25 nM) or ¹²⁵I GRO- α and 0.5 μ g/mL of IL-8R α or 1.0 μ g/mL of IL-8R β membranes in 20 mM Bis-Trispropane and 0.4 mM Tris HCl buffers, pH 8.0, containing 1.2 mM MgSO₄, 0.1 mM EDTA, 25 mM Na and 0.03% CHAPS. In addition, drug or compound of

15 interest is added which has been pre-dissolved in DMSO so as to reach a final concentration of between 0.01nM and 100 μ M. The assay is initiated by addition of ¹²⁵I-IL-8. After 1 hour at room temperature the plate is harvested using a Tomtec 96-well harvester onto a glass fiber filtermat blocked with 1% polyethylenimine/ 0.5% BSA and washed 3 times with 25 mM NaCl, 10 mM TrisHCl, 1 mM MgSO₄,

20 0.5 mM EDTA, 0.03 % CHAPS, pH 7.4. The filter is then dried and counted on the Betaplate liquid scintillation counter. The recombinant IL-8 R α , or Type I, receptor is also referred to herein as the non-permissive receptor and the recombinant IL-8 R β , or Type II, receptor is referred to as the permissive receptor.

Representative compounds of Formula (I), Examples 1 to 106 have

25 exhibited positive inhibitory activity in this assay at IC₅₀ levels < 30 μ M.

Chemotaxis Assay:

The *in vitro* inhibitory properties of these compounds are determined in the neutrophil chemotaxis assay as described in Current Protocols in Immunology, vol. I, Suppl 1, Unit 6.12.3., whose disclosure is incorporated herein by reference in its

30 entirety. Neutrophils were isolated from human blood as described in Current Protocols in Immunology Vol. I, Suppl 1 Unit 7.23.1, whose disclosure is

103
109

incorporated herein by reference in its entirety. The chemoattractants IL-8, GRO- α , GRO- β , GRO- γ and NAP-2 are placed in the bottom chamber of a 48 multiwell chamber (Neuro Probe, Cabin John, MD) at a concentration between 0.1 and 100 nM. The two chambers are separated by a 5 μ M polycarbonate filter. When compounds of this invention are tested, they are mixed with the cells (0.001 - 1000 nM) just prior to the addition of the cells to the upper chamber. Incubation is allowed to proceed for between about 45 and 90 min at about 37°C in a humidified incubator with 5% CO₂. At the end of the incubation period, the polycarbonate membrane is removed and the top side washed, the membrane then stained using the Diff Quick staining protocol (Baxter Products, McGaw-Park, IL, USA). Cells which have chemotaxed to the chemokine are visually counted using a microscope. Generally, four fields are counted for each sample, these numbers are averaged to give the average number of cells which had migrated. Each sample is tested in triplicate and each compound repeated at least four times. To certain cells (positive control cells) no compound is added, these cells represent the maximum chemotactic response of the cells. In the case where a negative control (unstimulated) is desired, no chemokine is added to the bottom chamber. The difference between the positive control and the negative control represents the chemotactic activity of the cells.

Elastase Release Assay:

The compounds of this invention are tested for their ability to prevent Elastase release from human neutrophils. Neutrophils are isolated from human blood as described in Current Protocols in Immunology Vol. I, Suppl 1 Unit 7.23.1. PMNs 0.88×10^6 cells suspended in Ringer's Solution (NaCl 118, KCl 4.56, NaHCO₃ 25, KH₂PO₄ 1.03, Glucose 11.1, HEPES 5 mM, pH 7.4) are placed in each well of a 96 well plate in a volume of 50 μ l. To this plate is added the test compound (0.001 - 1000 nM) in a volume of 50 μ l, Cytochalasin B in a volume of 50 μ l (20ng/ml) and Ringers buffer in a volume of 50 μ l. These cells are allowed to warm (37 °C, 5% CO₂, 95% RH) for 5 min before IL-8, GRO α , GRO β , GRO γ or NAP-2 at a final concentration of 0.01 - 1000 nM was added. The reaction is allowed to proceed for 45 min before the 96 well plate is centrifuged (800 xg 5 min.) and 100 μ l of the supernatant removed. This supernatant is added to a second 96 well plate followed

41

000780-07488709

104
HO

by an artificial elastase substrate (MeOSuc-Ala-Ala-Pro-Val-AMC, Nova Biochem, La Jolla, CA) to a final concentration of 6 ug/ml dissolved in phosphate buffered saline. Immediately, the plate is placed in a fluorescent 96 well plate reader (Cytofluor 2350, Millipore, Bedford, MA) and data collected at 3 min intervals according to the method of Nakajima et al J. Biol. Chem. 254 4027 (1979). The amount of Elastase released from the PMNs is calculated by measuring the rate of MeOSuc-Ala-Ala-Pro-Val-AMC degradation.

TNF- α in Traumatic Brain Injury Assay

The present assay provides for examination of the expression of tumor necrosis factor mRNA in specific brain regions, which follow experimentally, induced lateral fluid-percussion traumatic brain injury (TBI) in rats. Adult Sprague-Dawley rats (n=42) were anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and subjected to lateral fluid-percussion brain injury of moderate severity (2.4 atm.) centered over the left temporoparietal cortex (n=18), or "sham" treatment (anesthesia and surgery without injury, n=18). Animals are sacrificed by decapitation at 1, 6 and 24 hr. post injury, brains removed, and tissue samples of left (injured) parietal cortex (LC), corresponding area in the contralateral right cortex (RC), cortex adjacent to injured parietal cortex (LA), corresponding adjacent area in the right cortex (RA), left hippocampus (LH) and right hippocampus (RH) are prepared. Total RNA are isolated and Northern blot hybridization is performed and quantitated relative to an TNF- α positive control RNA (macrophage = 100%). A marked increase of TNF- α mRNA expression is observed in LH (104 $\pm$ 17% of positive control, p < 0.05 compared with sham), LC (105 $\pm$ 21%, p < 0.05) and LA (69 $\pm$ 8%, p < 0.01) in the traumatized hemisphere 1 hr. following injury. An increased TNF- α mRNA expression is also observed in LH (46 $\pm$ 8%, p < 0.05), LC (30 $\pm$ 3%, p < 0.01) and LA (32 $\pm$ 3%, p < 0.01) at 6 hr which resolves by 24 hr following injury. In the contralateral hemisphere, expression of TNF- α mRNA is increased in RH (46 $\pm$ 2%, p < 0.01), RC (4 $\pm$ 3%) and RA (22 $\pm$ 8%) at 1 hr and in RH (28 $\pm$ 11%), RC (7 $\pm$ 5%) and RA (26 $\pm$ 6%, p < 0.05) at 6 hr but not at 24 hr following injury. In sham (surgery without injury) or naive animals, no consistent changes in expression of TNF- α mRNA are observed in any of the 6 brain areas in either hemisphere at any times. These results indicate that following parasagittal fluid-percussion brain injury, the temporal expression of TNF- α mRNA is altered in specific brain regions, including those of the non-traumatized hemisphere. Since

60188410-031000

105
TH

TNF- α is able to induce nerve growth factor (NGF) and stimulate the release of other cytokines from activated astrocytes, this post-traumatic alteration in gene expression of TNF- α plays an important role in both the acute and regenerative response to CNS trauma.

CNS Injury model for IL-1 β mRNA

5 This assay characterizes the regional expression of interleukin-1 β (IL-1 β) mRNA in specific brain regions following experimental lateral fluid-percussion traumatic brain injury (TBI) in rats. Adult Sprague-Dawley rats (n=42) are anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and subjected to lateral fluid-percussion brain injury of moderate severity (2.4 atm.) centered over the left
10 temporoparietal cortex (n=18), or "sham" treatment (anesthesia and surgery without injury). Animals are sacrificed at 1, 6 and 24 hr. post injury, brains removed, and tissue samples of left (injured) parietal cortex (LC), corresponding area in the contralateral right cortex (RC), cortex adjacent to injured parietal cortex (LA), corresponding adjacent area in the right cortex (RA), left hippocampus (LH) and
15 right hippocampus (RH) are prepared. Total RNA is isolated and Northern blot hybridization was performed and the quantity of brain tissue IL-1 β mRNA is presented as percent relative radioactivity of IL-1 β positive macrophage RNA which was loaded on the same gel. At 1 hr following brain injury, a marked and significant increase in expression of IL-1 β mRNA is observed in LC (20.0 $\pm$ 0.7% of positive
20 control, n=6, p < 0.05 compared with sham animal), LH (24.5 $\pm$ 0.9%, p < 0.05) and LA (21.5 $\pm$ 3.1%, p < 0.05) in the injured hemisphere, which remained elevated up to 6 hr. post injury in the LC (4.0 $\pm$ 0.4%, n=6, p < 0.05) and LH (5.0 $\pm$ 1.3%, p < 0.05). In sham or naive animals, no expression of IL-1 β mRNA is observed in any of the respective brain areas. These results indicate that following TBI, the temporal
25 expression of IL-1 β mRNA is regionally stimulated in specific brain regions. These regional changes in cytokines, such as IL-1 β play a role in the post-traumatic.

30 All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

 The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments

5018410-031000

106
H2

specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the

5 scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.


60188410-031000

107 HJ


What is Claimed Is:

1. A compound of the formula (I):

5



wherein



10

wherein

R_b is independently selected from the group consisting of hydrogen, NR_6R_7 , OH, OR_a , C_{1-5} alkyl, aryl, aryl C_{1-4} alkyl, aryl C_{2-4} alkenyl, cycloalkyl, cycloalkyl C_{1-5} alkyl, heteroaryl, heteroaryl C_{1-4} alkyl, heteroaryl C_{2-4} alkenyl, heterocyclic, heterocyclic C_{1-4} alkyl, and a heterocyclic C_{2-4} alkenyl moiety, all of which moieties may be optionally substituted one to three times independently by a substituent selected from the group consisting of halogen, nitro, halosubstituted C_{1-4} alkyl, C_{1-4} alkyl, amino, mono or di- C_{1-4} alkyl substituted amine, $OR_aC(O)R_a$, $NR_aC(O)OR_a$, $OC(O)NR_6R_7$, hydroxy, $NR_9C(O)R_a$, $S(O)_mR_a$, $C(O)NR_6R_7$, $C(O)OH$, $C(O)OR_a$, $S(O)_2NR_6R_7$ and $NHS(O)_2R_a$; or the two R_b substituents join to form a 3-10 membered ring, optionally substituted and containing, in addition to carbon, independently, 1 to 3 optionally substituted moieties selected from the group consisting of NR_a , O, S, SO, and SO_2 ; R_a is selected from the group consisting of alkyl, aryl, aryl C_{1-4} alkyl, heteroaryl, heteroaryl C_{1-4} alkyl, heterocyclic, $COOR_a$,

20

48

5018410-031000

108
114

and a heterocyclic C₁₋₄alkyl moiety, all of which moieties may be optionally substituted;

m is an integer having a value of 1 to 3;

m' is 0, or an integer having a value of 1 or 2;

5 n is an integer having a value of 1 to 3;

q is 0, or an integer having a value of 1 to 10;

t is 0, or an integer having a value of 1 or 2;

s is an integer having a value of 1 to 3;

R₁ is independently selected from the group consisting of hydrogen, halogen, nitro,

10 cyano, C₁₋₁₀ alkyl, halosubstituted C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₁₋₁₀ alkoxy, halosubstituted C₁₋₁₀alkoxy, azide, S(O)_tR₄, (CR_gR_g)_q S(O)_tR₄, hydroxy, hydroxy substituted C₁₋₄alkyl, aryl, aryl C₁₋₄ alkyl, aryl C₂₋₁₀ alkenyl, aryloxy, aryl C₁₋₄ alkyloxy, heteroaryl, heteroarylalkyl, heteroaryl C₂₋₁₀ alkenyl, heteroaryl C₁₋₄ alkyloxy, heterocyclic, heterocyclic C₁₋₄alkyl, heterocyclicC₁₋₄alkyloxy,
15 heterocyclicC₂₋₁₀ alkenyl, (CR_gR_g)_q NR₄R₅, (CR_gR_g)_q C(O)NR₄R₅, C₂₋₁₀ alkenyl C(O)NR₄R₅, (CR_gR_g)_q C(O)NR₄R₁₀, S(O)₃R₈, (CR_gR_g)_q C(O)R₁₁, C₂₋₁₀ alkenyl C(O)R₁₁, C₂₋₁₀ alkenyl C(O)OR₁₁, (CR_gR_g)_q C(O)OR₁₁, (CR_gR_g)_q OC(O)R₁₁, (CR_gR_g)_q NR₄C(O)R₁₁, (CR_gR_g)_q C(NR₄)NR₄R₅, (CR_gR_g)_q NR₄C(NR₅)R₁₁, (CR_gR_g)_q NHS(O)₂R₁₃, and (CR_gR_g)_q S(O)₂NR₄R₅; or two R₁ moieties together
20 may form O-(CH₂)_sO or a 5 to 6 membered saturated or unsaturated ring, such that the alkyl, aryl, arylalkyl, heteroaryl, or heterocyclic moieties may be optionally substituted;

R₄ and R₅ are independently selected from the group consisting of hydrogen, optionally substituted C₁₋₄ alkyl, optionally substituted aryl, optionally substituted aryl C₁₋

25 4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C₁₋₄alkyl, heterocyclic, and heterocyclicC₁₋₄ alkyl, or R₄ and R₅ together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O, N and S;

R₆ and R₇ are independently selected from the group consisting of hydrogen, a C₁₋₄

30 alkyl, heteroaryl, aryl, alkyl aryl, and alkyl C₁₋₄ heteroalkyl; or R₆ and R₇ together

60188410-031000

109
HS

with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom which is selected from the group consisting of oxygen, nitrogen or sulfur, and which ring may be optionally substituted;

- 5 Y is selected from the group consisting of furan, thiophene, pyrrole, oxazole, imidazole, thiazole, pyrazole, isooxazole, isothiazole, 1,2,3 or 1,2,4 oxadiazole, 1,2,3 or 1,2,4 triazole, 1,2,3 or 1,2,4 thiadiazole, pyridine, pyrimidine, pyridazine, pyrazine, 1,3,5, or 1,2,3 or 1,2,4 triazine, 1,2,4,5 tetrazine, indole, benzofuran, indazole, benzimidazole, benzothiazole, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline and quinoxaline all of which moieties can be substituted 1-3 times with R₁

R₈ is hydrogen or C₁₋₄ alkyl;

R₉ is hydrogen or a C₁₋₄ alkyl;

R₁₀ is C₁₋₁₀ alkyl C(O)₂R₈;

- 15 R₁₁ is selected from the group consisting of hydrogen, optionally substituted C₁₋₄ alkyl, optionally substituted aryl, optionally substituted aryl C₁₋₄alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC₁₋₄alkyl, optionally substituted heterocyclic, and optionally substituted heterocyclicC₁₋₄alkyl; and

- 20 R₁₃ is selected from the group consisting of C₁₋₄ alkyl, aryl, aryl C₁₋₄alkyl, heteroaryl, heteroarylC₁₋₄alkyl, heterocyclic, and heterocyclicC₁₋₄alkyl; or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1 wherein R₁ is substituted in the 4- position by an electron withdrawing moiety.
3. The compound according to Claim 2 wherein R₁ is halogen, methyl, cyano or .
- 25 nitro.
4. The compound according to Claim 3 wherein R₁ is halogen.
5. The compound according to Claim 4 wherein R₁ is independently, fluorine, chlorine, or bromine.
6. The compound according to Claim 1 wherein Y is mono-substituted in the 2'-
- 30 position or 3'- position, or is disubstituted in the 2'- or 3'- position of a monocyclic ring.

50188410-031000

24

110
118

7. The compound according to Claim 6 wherein Y is pyridine and pyrazole.
8. The compound according to Claim 1 wherein R_b is hydrogen, C₁₋₄ alkyl, or C₁₋₄ alkyl substituted with C(O)OH, or C(O)OR_a.
9. The compound according to Claim 1 which is:
- 5 N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(pyridin-2-yl)urea;
N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(2-chloro-pyridin-3-yl)urea;
N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(1-phenyl-1H-1,2,3-triazol-5-yl)urea;
N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(1,3-dimethylpyrazol-5-yl)urea;
- 10 N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(1-methylpyrazol-5-yl)urea; and
N-(3-aminosulfonyl-4-chloro-2-hydroxyphenyl)-N'-(2-methyl-pyridin-3-yl)urea.
10. A compound according to claim 9 wherein the compound is in its sodium salt form.
11. A compound according to claim 10 wherein the compound is in its potassium salt form.
12. A pharmaceutical composition comprising a compound according to any of Claims 1 to 11 and a pharmaceutically acceptable carrier or diluent.
13. A method of treating a chemokine mediated disease, wherein the chemokine binds to an IL-8 a or b receptor in a mammal, which method comprises administering to said mammal an effective amount of a compound of the formula according to any one of Claims 1 to 11.)
14. The method according to Claim 13 wherein the mammal is afflicted with a chemokine mediated disease selected from the group consisting of:
- psoriasis, atopic dermatitis, osteo arthritis, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, stroke, septic shock, multiple sclerosis, endotoxic shock, gram negative sepsis, toxic shock syndrome, cardiac and renal reperfusion injury, glomerulonephritis, thrombosis, graft vs. host reaction, Alzheimer's disease, allograft rejections, malaria, restenosis, angiogenesis, atherosclerosis, osteoporosis, gingivitis and undesired hematopoietic stem cells release and diseases caused by respiratory viruses, herpes viruses, and hepatitis viruses, meningitis, cystic fibrosis, pre-term labor, cough, pruritus, multi-organ

6018410-031000

48

111
H2

- dysfunction, trauma, strains, sprains, contusions, psoriatic arthritis, herpes, encephalitis, CNS vasculitis, traumatic brain injury, CNS tumors, subarachnoid hemorrhage, post surgical trauma, interstitial pneumonitis, hypersensitivity, crystal induced arthritis, acute and chronic pancreatitis, acute alcoholic hepatitis,
- 5 necrotizing enterocolitis, chronic sinusitis, uveitis, polymyositis, vasculitis, acne, gastric and duodenal ulcers, celiac disease, esophagitis, glossitis, airflow obstruction, airway hyperresponsiveness, bronchiolitis obliterans organizing pneumonia, bronchiectasia, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, cor pulmonae, dyspnea, emphysema, hypercapnea, hyperinflation, hypoxemia,
- 10 hyperoxia-induced inflammations, hypoxia, surgical lung volume reduction, pulmonary fibrosis, pulmonary hypertension, right ventricular hypertrophy, sarcoidosis, small airway disease, ventilation-perfusion mismatching, wheeze, colds and lupus.

60188410.031000

49

112
118

ABSTRACT

This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

0007E0-0F488T09

50

Señores

DIVISION DE NUEVAS CREACIONES

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Bogotá, D.C.

Re.: Expediente No. 01 - 19.686
Solicitud de Patente

SUPERINTENDENCIA Y COMERCIO
Radicación : 01019686 00000001 Folios: 50
Fecha (UND): 2001-03-30 12:58:44
Trámite : 002 PATENTES D I REGISTRAR 329 COMPLETA
Dependencia: 2000 DIVISION DE NUEVAS CREACIONES

Debidamente traducida, adjunto acompaño la copia oficial de la solicitud de patente básica estadounidense No. 60/188.410 la cual le solicito agregar a este expediente para los efectos legales respectivos.

De Ustedes atentamente,

GERMAN CASTILLO GRAU

T.P. No. 2978 del C.S.J.

Expediente No		01019686	No de Follo
Item		No de unidades	
1	CD		
2	DVD		
3	REVISTA		
4	LIBRO		
5	PERIODICO		
6	DISQUETES		
7	SOBRE DE MANILA		
8	SOBRE BLANCO TAMAÑO CARTA		
9	SOBRE BLANCO TAMAÑO OFICIO	✓ 1	
10	OTROS:		

Observaciones: **ESTE FINAL**

2do. EXAMEN DE FORMA PATENTE DE INVENCION

Folio 182

Radicación no 01-19686

Concepto Técnico no 1802

Clasificación Internacional de Patentes A61K 31/17_

Practicado el examen de acuerdo a lo establecido en el Art. 38 de la Decisión 486 se determinó que esta solicitud de Patente de Invención:

- SI [☒] NO [☐] Contiene un resumen de la invención (Art.26-e).
- SI [☒] NO [☐] Contiene el título o nombre de la invención (Art.27-d).
- SI [☒] NO [☐] Contiene la descripción de la invención (Art.26-b).
- SI [☒] NO [☐] NO ES APLICABLE [☐] Contiene los dibujos necesarios para comprender la invención (Art.26-d)
- SI [☒] NO [☐] Contiene una o más reivindicaciones. (Art.26-c).
- SI [☐] NO [☐] NO ES APLICABLE [☒] Han sido desarrollados los productos y/o procedimientos a partir de recursos genéticos o de sus productos derivados de los que cualquiera de los Países Miembros es país de origen. (Art. 26- h).
- SI [☐] NO [☐] NO ES APLICABLE [☒] Los productos y/o procedimientos han sido obtenidos o desarrollados a partir de los conocimientos tradicionales de las comunidades indígenas, afroamericanas, o locales de los países miembros, de acuerdo a lo establecido en la Decisión 391 y sus modificaciones y reglamentaciones vigentes.(Art.26-l).
- SI [☐] NO [☒] La invención se refiere a un producto relativo a un material biológico. (Art.26-j).
- SI [☒] NO [☐] La prioridad coincide con la materia reivindicada.
- SI [☒] NO [☐] **CUMPLE LOS REQUISITOS TÉCNICOS**

OBSERVACIONES Y OTROS: SI [☐] NO [☒] ver hoja(s) anexa(s)

EXAMINADOR TÉCNICO
202050

Bogotá D. C., DICIEMBRE 12 DEL 2002

Folio 188

2020
Bogotá DC

Doctor(a)
GERMAN CASTILLO GRAU
Apoderado(a)

REFERENCIA:	Radicación No.	01-19886
	Trámite	002
	Evento	001
	Actuación	416
	Oficio No.	2326
	Folios	001

Teniendo en cuenta que la solicitud de privilegio de patente que se tramita bajo el expediente indicado en la referencia, reúne los requisitos de forma establecidos en los artículos 26 y 27 de la Decisión 486 de la Comisión de la Comunidad Andina, y en las demás disposiciones vigentes sobre la materia, se envía el extracto de la solicitud a la Oficina de Comunicaciones para efecto de su publicación en la Gaceta de Propiedad Industrial, conforme lo establece el artículo 40 de la misma Decisión.

Cúmplase
Dado en Bogotá DC, a los 17 DIC. 2002


ALIX CARMENZA CÉSPEDES DE VERGEL
Jefe de la División de Nuevas Creaciones

202050

527